The scientific clinical study of antibody therapy

CCR4是一种趋化因子受体，选择性表达于Treg和Th2细胞。由于我们以前发现CCR4在某些类型的T细胞白血病/淋巴瘤上有表达，我们推测该分子可能是治疗难治性T细胞白血病/淋巴瘤的一个新的分子靶点。因此，我们开发了下一代抗CCR4单抗，其Fc区域被脱糖，导致高度增强的ADCC。基于我们对CCR4的实验室工作，以及这项翻译研究的成功，我们已经完成了针对日本CCR4阳性T细胞白血病/淋巴瘤患者的抗CCR4单抗的I和II期临床试验，并正在准备向监管机构申请批准的过程中。

CCR4 is a chemokine receptor selectively expressed on Treg and Th2 cells. Because we previously found that CCR4 is expressed on certain types of T-cell leukemia/lymphoma, we postulated that this molecule might represent a novel molecular target for immunotherapy against refractory T-cell leukemia/lymphoma. Accordingly, we have developed a next-generation anti-CCR4 mAb, the Fc region of which is defucosylated, resulting in highly enhanced ADCC. Based on our laboratory work on CCR4, and as an outcome of the success of this translational research, we have completed phase I & II clinical trials of anti-CCR4 mAb in patients with CCR4-positive T-cell leukemia/lymphoma in Japan, and are in the process of preparing an application to the regulatory authority for approval.